L-Tryptophan methyl ester hydrochloride High-Purity Amino Acid Derivative for Peptide Synthesis & Biochemical Research

As a high-purity pharmaceutical intermediate, L-Tyrosine Ethyl Ester Hydrochloride is predominantly utilized in the chemical synthesis of bioactive peptides, dopamine analogs, and melanin precursors. Its excellent solubility profile makes it an ideal chiral building block for asymmetric synthesis and a critical substrate in enzymatic reactions. Available in purity grades of ≥98% (HPLC), it meets stringent requirements for R&D and cGMP manufacturing processes. Reliable supply ensures batch-to-batch consistency for long-term project scalability.

Vidarabine is classified as a potential reproductive hazard and an irritant. Safety Data Sheets (SDS) mandate the following:

• Hazard Statements (H360): May damage fertility or the unborn child (Category 1B).

• Precautionary Measures: Use fume hoods and wear impermeable gloves (e.g., nitrile), lab coats, and safety goggles. Avoid generating airborne dust.

• First Aid: In case of skin contact, wash immediately with copious soap and water. If inhaled, move to fresh air.

• Storage: Store in tightly sealed, light-resistant containers at 2°C to 8°C (refrigerated) for long-term stability. Avoid freezing.

• 
  

While superseded by newer nucleoside analogs (Acyclovir, Ganciclovir) for systemic use due to better bioavailability and lower toxicity, Vidarabine retains niche value. Its primary current application is ophthalmic ointment (3%) . Pharmacokinetically, the raw material has poor oral bioavailability (<10%) and is rapidly deaminated in the gastrointestinal tract, necessitating parenteral or topical administration.

Vidarabine API is a well-characterized, stable crystalline nucleoside analog. While its systemic use has declined, it remains a critical raw material for topical antiviral ophthalmic preparations, particularly where resistance to other agents occurs. Manufacturers must strictly control impurities (especially Ara-Hx) and water content to ensure final drug product efficacy.